Privately-held Mindbeam AI said its latest research suggests generative artificial intelligence could accelerate the search for safer pain medications by identifying novel compounds with improved predicted liver safety compared with acetaminophen, while also shortening the early stages of drug discovery.
A member of the NVIDIA Inception program for startups, Mindbeam AI develops infrastructure aimed at optimizing large language model training and inference, with a focus on improving performance and resource efficiency using NVIDIA Inc (NASDAQ:NVDA) GPU-based computing.
The company said its preliminary findings demonstrate how AI-powered drug design can broaden the pool of potential pain therapies by combining generative AI with computational modeling and virtual screening techniques.
Three Lead Compounds Emerged From Virtual Screening
Mindbeam designed and evaluated 24 novel drug candidates targeting TRPV1, a receptor involved in pain signaling.
